Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists regarding the field of genitourinary malignancies.

Community oncologists should focus on the results of the STAMPEDE and CHAARTED studies, which demonstrate level one evidence that patients with newly diagnosed metastatic prostate cancer who receive docetaxel in combination with androgen deprivation therapy (ADT) have a significant overall survival benefit. With this regimen, the life expectancy is increased from 1 year to nearly 1.5 years, Kibel explains.

Secondly, it is important to treat patients who develop bone metastases, he adds. The number of skeletal events decreases when patients receive docetaxel and ADT, and they will also have an improved quality of life.

View more from the 2016 GU Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Genitourinary Cancers Symposium (ASCO GU)

Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.

Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers